PCK1 and type 2 diabetes mellitus: Interestingly, a recent study has shown that liver-specific silencing of Pck1 can improve glycaemic control and insulin sensitivity in a T2D mouse model [17], supporting the role of PEPCK-C in T2D pathology and providing a potential therapeutic target for treatment of the disease.